Innovation in Molecular Transmutation and Drug Discovery

Our Innovation

OUR INNOVATION STRATEGY

Innovation needs to thrive with a long-term horizon, developed as a core set of platforms, and fostered as the heart of our non-profit Institute.

Innovation needs to move across boundaries, and innovation as it develops needs to be tempered by the fire of high-urgency medical projects. Drug discovery projects are set up both within the internal drug discovery pipeline as well as through partnerships and/or spin-offs and licensing into the for-profit sector.

Thus the benefits, and strengths, of forming affiliated expert investor communities is a vital part of the strategy as well.

OPPORTUNITY & INSIGHT

Institute for Molecular Intelligence™

Powering AI's Fundamental ability to perceive Chemistry

The power of AI in the design and optimization of new medicines is on the cusp of launching into a new era.  Today's deep neural nets are, however, hampered by the use of mere shadows of molecular information, due to the traditions of standard internet languages for structure and data.  Hampered by "linear thinking".

Access to molecular properties essential for creative and truly valuable generative molecular design,  for example for medicinal R&D, is enabled by the novel approaches being championed by the Institute for Molecular Intelligence™.

CAPABILITIES & DELIVERABLES

The genomes of the target microbes, as well as the genomic networks within disease-mediating pathways in humans, are fed into the Institute’s computational chemogenomics technology.

For each disease area, the next steps depend on the relative merits of known disease biology that prioritize specific protein targets up front, or the methodical and efficient selection of targets within a pathway based on the drugability evaluation that is intrinsic to the Institute’s core methods.

Deliverables include

  • the de novo discovery of bio-active ligands against specific enzyme targets;

  • acceleration of R&D projects towards innovative INDs by a new approach to guided lead optimization;

  • the core technology applied to scan diverse genomes, or specified disease-relevant gene networks, for accessible paths to drugability;

  • improving upon and innovating from clinically-proven drug candidates through scaffold hopping.

OUR INNOVATION builds on recently established chemogenomic technologies and now augmented through physics-informed AI